{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:15:03Z","timestamp":1761581703852,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s12032-018-1156-x","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T06:53:31Z","timestamp":1527576811000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Is there a role for immunotherapy in malignant pleural mesothelioma?"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0859-7847","authenticated-orcid":false,"given":"Alfredo","family":"Tartarone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Lerose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Aieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"1156_CR1","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1097\/JTO.0b013e3181f1cf2b","volume":"5","author":"MT Milano","year":"2010","unstructured":"Milano MT, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol. 2010;5:1841\u20138.","journal-title":"J Thorac Oncol"},{"key":"1156_CR2","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.21037\/jtd.2017.11.55","volume":"9","author":"E Taioli","year":"2017","unstructured":"Taioli E, van Gerwen M, Mihalopoulos M, Moskowitz G, Liu B, Flores R. Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery. J Thorac Dis. 2017;9:5423\u201333.","journal-title":"J Thorac Dis"},{"key":"1156_CR3","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"1156_CR4","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed (MAPS): a randomized, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405\u201314.","journal-title":"Lancet"},{"key":"1156_CR5","doi-asserted-by":"publisher","first-page":"v31-v39","DOI":"10.1093\/annonc\/mdv199","volume":"26","author":"P Baas","year":"2015","unstructured":"Baas P, Fennel D, Kerr KM, Van Schil PE, Haas RL, Petres S. Malignant pleural mesothelioma: ESMO clinical practice guidelines. Ann Oncol. 2015;26:v31-v39.","journal-title":"Ann Oncol"},{"key":"1156_CR6","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","volume":"36","author":"HL Kindler","year":"2018","unstructured":"Kindler HL, Ismaila N, Armato SG, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1343\u201373.","journal-title":"J Clin Oncol"},{"key":"1156_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","volume":"21","author":"GL Beatty","year":"2015","unstructured":"Beatty GL, Gladney WL. Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res. 2015;21:687\u201392.","journal-title":"Clin Cancer Res"},{"key":"1156_CR8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1156_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1053\/j.seminoncol.2010.09.001","volume":"37","author":"MK Callahan","year":"2010","unstructured":"Callahan MK, Wolchok JD, Allison JP. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol. 2010;37:473\u201384.","journal-title":"Semin Oncol"},{"key":"1156_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"1156_CR11","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.13895","volume":"8","author":"Y Dong","year":"2017","unstructured":"Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8:2171\u201386.","journal-title":"Oncotarget"},{"key":"1156_CR12","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Ateins M, et al. First-line nivolumab in stage IV or recurrent non small cell lung cancer. N Engl J med. 2017;376:2415\u201326.","journal-title":"N Engl J med"},{"key":"1156_CR13","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1 positive non small cell lung cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"1156_CR14","doi-asserted-by":"publisher","first-page":"e161-172","DOI":"10.1016\/S1470-2045(18)30100-1","volume":"19","author":"A Scherpereel","year":"2018","unstructured":"Scherpereel A, Wallyn F, Albelda SM, Munck C. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018;19:e161-172.","journal-title":"Lancet Oncol"},{"key":"1156_CR15","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jtho.2017.09.1968","volume":"13","author":"NS Patil","year":"2018","unstructured":"Patil NS, Righi L, Koeppen H, Zou W, Izzo S, Grosso F, et al. Molecular and histopathological characterization of the tumor immune microenvironment in advanced stage of malignant pleural mesothelioma. J Thorac Oncol. 2018;13:124\u201333.","journal-title":"J Thorac Oncol"},{"key":"1156_CR16","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","volume":"14","author":"L Calabr\u00f2","year":"2013","unstructured":"Calabr\u00f2 L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single arm, phase 2 trial. Lancet Oncol. 2013;14:1104\u201311.","journal-title":"Lancet Oncol"},{"key":"1156_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","volume":"3","author":"L Calabr\u00f2","year":"2015","unstructured":"Calabr\u00f2 L, Morra A, Fosatti F, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma. An open-label, single arm, phase 2 study. Lancet Respir Med. 2015;3:301\u20139.","journal-title":"Lancet Respir Med"},{"key":"1156_CR18","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","volume":"18","author":"M Maio","year":"2017","unstructured":"Maio M, Scherpereel A, Calabr\u00f2 L, Aerts J, Cedres Perez S, Bears A, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicenter, international, randomized, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18:1261\u201373.","journal-title":"Lancet Oncol"},{"key":"1156_CR19","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","volume":"18","author":"EW Alley","year":"2017","unstructured":"Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18:623\u201330.","journal-title":"Lancet Oncol"},{"key":"1156_CR20","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.1016\/j.jtho.2016.11.301","volume":"12","author":"H Kindler","year":"2017","unstructured":"Kindler H, Karrison T, Carol Tan YH, Rose B, Ahmad M, Straus C, Sargis R, Seiwert T. Phase II trial of pembrolizumab in patients with malignant mesothelioma: interim analysis. J Thorac Oncol. 2017;12:S293. abstract OA13.02.","journal-title":"J Thorac Oncol"},{"issue":"suppl 11","key":"1156_CR21","first-page":"xi6-xi29","volume":"28","author":"L Mauti","year":"2017","unstructured":"Mauti L, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, et al. Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM)- outcomes in real-life setting in Australia (AUS) and Switzerland (CH). Ann Oncol. 2017;28(suppl 11):xi6-xi29.","journal-title":"Ann Oncol"},{"key":"1156_CR22","doi-asserted-by":"publisher","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","volume":"12","author":"J Quispel-Janssen","year":"2017","unstructured":"Quispel-Janssen J, Zago G, Schouten R, Buikhulsen W, Monkhorst K, Thunissen E, Bass P. A Phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopsies. J Thorac Oncol. 2017;12:S292. abstract OA13.01.","journal-title":"J Thorac Oncol"},{"key":"1156_CR23","doi-asserted-by":"publisher","first-page":"S1883","DOI":"10.1016\/j.jtho.2017.09.634","volume":"12","author":"Y Goto","year":"2017","unstructured":"Goto Y, Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, et al. A phase II study of nivolumab: a multicenter, open-label, single arm study in malignant pleural mesothelioma (MERIT). J Thorac Oncol. 2017;12:S1883. abstract MA 19.01.","journal-title":"J Thorac Oncol"},{"key":"1156_CR24","doi-asserted-by":"crossref","unstructured":"Hassan R, Thomas A, Nemunaitis JJ, Patel MR, Bennouna J, Chen F, et al. Avelumab in patients with previously treated mesothelioma: updated phase Ib results from the JAVELIN solid tumor trial. J Clin Oncol 2018;36: Suppl 5S abstr 166.","DOI":"10.1200\/JCO.2018.36.5_suppl.166"},{"issue":"suppl 5","key":"1156_CR25","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/annonc\/mdx440.074","volume":"28","author":"G Zalcman","year":"2017","unstructured":"Zalcman G, Mazieres J, Greillier L, Lantuejoul S, Do P, Bylicki O, et al. Second or 3rd line nivolumab (NIVO) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. Ann Oncol. 2017;28(suppl 5):648. (LBA58 PR).","journal-title":"Ann Oncol"},{"key":"1156_CR26","doi-asserted-by":"publisher","first-page":"abstr8558","DOI":"10.1200\/JCO.2017.35.15_suppl.8558","volume":"35","author":"L Calabr\u00f2","year":"2017","unstructured":"Calabr\u00f2 L, Morra A, Giannarelli D, et al. Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: safety analysis from the phase II NIBIT-MESO-1 study. J Clin Oncol. 2017;35:abstr8558.","journal-title":"J Clin Oncol"},{"key":"1156_CR27","doi-asserted-by":"publisher","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.329","volume":"12","author":"M Disselhorst","year":"2017","unstructured":"Disselhorst M, Harms E, Van Tinteren H, Quispel-Janssen J, Monkhorst K, Burgers S, Baas P. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma: a phase II study. J Thorac Oncol. 2017;12:S1746. abstract OA 02.02.","journal-title":"J Thorac Oncol"},{"issue":"Suppl 2","key":"1156_CR28","first-page":"S322-S332","volume":"10","author":"L Calabr\u00f2","year":"2018","unstructured":"Calabr\u00f2 L, Rossi G, Maio M. New horizons from immunotherapy in malignant pleural mesothelioma. J Thorac Dis. 2018;10(Suppl 2):S322-S332.","journal-title":"J Thorac Dis"},{"key":"1156_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ctrv.2014.10.007","volume":"41","author":"J Remon","year":"2015","unstructured":"Remon J, Reguart N, Corral J, Lianes P. Malignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategies. Cancer Treat Rev. 2015;41:27\u201334.","journal-title":"Cancer Treat Rev"},{"key":"1156_CR30","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.2147\/OTT.S145105","volume":"10","author":"P Baldo","year":"2017","unstructured":"Baldo P, Cecco S. Amatuximab and novel agents targeting mesothelin for solid tumors. Onco Targets Ther. 2017;10:5337\u201353.","journal-title":"Onco Targets Ther"},{"key":"1156_CR31","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","volume":"20","author":"R Hassan","year":"2014","unstructured":"Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014;20:5927\u201336.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 2","key":"1156_CR32","doi-asserted-by":"publisher","first-page":"S1746","DOI":"10.1016\/j.jtho.2017.09.328","volume":"12","author":"HL Kindler","year":"2017","unstructured":"Kindler HL, Novello S, Fennell DA, Blumenschein G, Bearz A, Ceresoli G, et al. Randomized phase II study of anetumab ravtansine or vinorelbine in patients with malignant pleural mesothelioma. J Thorac Oncol. 2017;12(Suppl 2):S1746. (Abstract OA 02.01).","journal-title":"J Thorac Oncol"},{"key":"1156_CR33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2217\/imt.16.4","volume":"8","author":"M O\u2019Hara","year":"2016","unstructured":"O\u2019Hara M, Stashwick C, Haas AR, Tanyi JL. Mesothelin as a target for chimeric antigen receptor-modified T cell as anticancer therapy. Immunotherapy. 2016;8:449\u201360.","journal-title":"Immunotherapy"},{"key":"1156_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/cancers9090115","volume":"9","author":"A Klampatsa","year":"2017","unstructured":"Klampatsa A, Haas AR, Moon EK, Albelda SM. Chimeric antigen receptor (CAR) T cell therapy for malignant pleural mesothelioma (MPM). Cancers 2017;9:115.","journal-title":"Cancers"},{"key":"1156_CR35","doi-asserted-by":"publisher","first-page":"e1363137","DOI":"10.1080\/2162402X.2017.1363137","volume":"6","author":"T Thayaparan","year":"2017","unstructured":"Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, et al. CAR-T-cell immunotherapy of MET-expressing malignant mesothelioma. Oncoimmunology. 2017;6:e1363137.","journal-title":"Oncoimmunology"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1156-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1156-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1156-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T19:00:09Z","timestamp":1604343609000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1156-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["1156"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1156-x","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"7 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"98"}}